Prévisions

Aucune donnée d'analyste n'est disponible pour cette entreprise.

Actualités Accéder au fil d'actualités

Bristol Myers Squibb distributes Eliquis via cost-plus platform

Bristol Myers Squibb will offer the anticoagulant Eliquis from April 27 through the Mark Cuban Cost Plus Drug Company on CostPlusDrugs.com. Patients with a prescription can buy a 30-day supply for $345 directly through the platform. The move is intended to expand direct and more transparent access to Eliquis and complements already existing direct-sales offerings for the drug. » Plus sur de.investing.com
Bristol Myers Squibb shows death cross as legacy drugs collapse and guidance steps down

Bristol Myers Squibb formed a technical death cross while Q4 2025 non-GAAP EPS missed by 22.7% after a $1.39bn acquired IPRD charge. Revenue ticked slightly higher but full-year 2026 guidance implies a step down, with Revlimid and Sprycel sales plunging 55% and 60% and generic pomalidomide expected in Q1 2026. The company’s pipeline offers binary FDA catalysts later in 2026, but these add risk rather than certainty for near-term fundamentals. » Plus sur finance.yahoo.com
Bristol Myers Squibb meets study goals with Reblozyl in alpha-thalassemia

The approval-relevant Phase 2 study of Reblozyl (luspatercept-aamt) met both primary and secondary endpoints in adults with alpha-thalassemia. In non–transfusion-dependent patients the mean hemoglobin level increased significantly, while in transfusion-dependent patients the transfusion burden decreased significantly. Safety data were consistent with the known profile; the data will be presented at an upcoming congress and discussed with the Chinese drug authority, and the study of adolescent cohorts is ongoing. » Plus sur de.investing.com